RMD downgraded to Hold by Canaccord Genuity, down from Buy. Stock fell 9% on October 29 after cutting FY26 growth guidance to mid-single-digit from high-single-digit, citing international weakness. Analyst consensus target remains $265.
Key data as of 3 Nov 2026
RMD downgraded to Hold by Canaccord Genuity, down from Buy. Stock fell 9% on October 29 after cutting FY26 growth guidance to mid-single-digit from high-single-digit, citing international weakness. Analyst consensus target remains $265.
ResMed heads into its July 30 earnings report with short sellers adding positions at a meaningful pace while options traders turn notably less defensive than usual. Short interest has climbed sharply over the past…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for RMD — free to start on ORTEX.
Sign up for free →Open RMD on ORTEX